Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy
Arthritis & Rheumatism2003Vol. 48(11), pp. 3224–3229
Citations Over TimeTop 1% of 2003 papers
Abstract
The daily, but not cumulative, GC dose was found to be a strong predictor of vertebral fracture in patients receiving GCs. At similar levels of BMD, postmenopausal women taking GCs, as compared with nonusers of GCs, had considerably higher risks of fracture.
Related Papers
- → A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia(2002)434 cited
- → Conditioned Placebo Analgesia Persists When Subjects Know They Are Receiving a Placebo(2015)116 cited
- → Μελέτη της πολυπαραγοντικής αναλγησίας στο μετεγχειρητικό πόνο μετά από λαπαροσκοπική χολοκυστεκτομή(2014)
- → Meta-meta-placebo and -curabo: You might get better just by reading this paper(2009)
- → (404) Use of a placebo run-in in clinical trials in patients with FM does not impact the response to pregabalin(2015)